株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インドの医薬品市場の見通し:購買力の強化、農村市場への普及、医療利用の拡大が、大手製薬会社の投資を集める

Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment

発行 GBI Research 商品コード 260639
出版日 ページ情報 英文 94 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
インドの医薬品市場の見通し:購買力の強化、農村市場への普及、医療利用の拡大が、大手製薬会社の投資を集める Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment
出版日: 2013年01月22日 ページ情報: 英文 94 Pages
概要

インドの医薬品市場は、2011年〜2015年のCAGRで、12%の成長が予測されています。

当レポートでは、インドの医薬品市場について調査分析し、市場の主要動向、問題点、課題について検証し、マクロ経済環境、産業の特徴、セグメント別の市場分析、年間の市場データ、主要企業プロファイルを提供し、ライセンスなどの取引分析も含めて、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 概要

  • 世界の医薬品産業の情勢
  • インドの医薬品部門のマクロ観点
  • 人口統計分析
  • 促進要因と障壁
  • インドの医薬品産業のSWOT分析

第4章 産業の特徴

  • 医療政策
  • インドの知的所有権
  • 医薬品配給構造
  • 国の医薬品価格政策
  • 物品サービス税
  • 直接税法
  • インドの医療費
  • 保険と償還

第5章 市場分析

  • 市場概要
  • 市場セグメンテーション

第6章 市場分析:治療カテゴリー別

  • 主な治療セグメントの市場シェア
  • 抗感染薬
  • 心臓血管系
  • 胃腸
  • 糖尿病
  • 中枢神経系
  • 呼吸器
  • 皮膚科
  • 腫瘍

第7章 主要動向

  • インドにおける医薬品産業の急速な統合と多国籍企業の台頭
  • 特許訴訟がジェネリックを支持
  • インドにおける農村市場の重要性の向上
  • 製品のローカライズとインド固有の価格設定
  • 販売戦略
  • ニッチ市場で紹介される特許取得製品
  • 偽造医薬品に対するインド政府の行動

第8章 競合情勢

  • 主な外国企業
    • Sanofi
    • Roche
    • AstraZeneca
    • GlaxoSmithKline
    • Abbott Laboratories
  • 主な国内企業
    • Dr. Reddy's Laboratories
    • Lupin
    • Cipla Limited
    • Ranbaxy Laboratories Limited
    • Biocon

第9章 将来の見通し

  • インドの医薬品産業の見通し
  • リスク
  • 提言
  • 機会
  • 将来の成功戦略

第10章 付録

図表

目次
Product Code: GBIHC275MR

Summary

GBI Research's new report "Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment" provides in-depth analysis of the trends, issues and challenges facing the Indian pharmaceutical market. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The Indian pharmaceutical industry grew from $0.8 billion in 1980 to $21.73 billion in 2010 and is expected to grow further as Multinational Companies (MNCs) enter the market. Although pharmaceutical giants such as GlaxoSmithKline (GSK) have been present in the market for years, the rising income of the middle-class population, changing patent laws, low-cost skilled labor and low-priced infrastructure in India have attracted other MNCs. With the current scenario, the market is expected to grow at a Compound Annual Growth Rate (CAGR) of 12% during the 2011-2015 period. Branded generics are expected to become more prevalent in India as many global players are planning to launch them after their patents expire.

The once highly fragmented Indian pharmaceutical industry is undergoing strategic consolidations with the aim of emerging as a highly organized sector. With the inflow of MNCs' R&D operations the industry will continue to experience a trend of M&A. Deals and acquisitions are set to continue due to low-cost infrastructure and labor as patent expiries and the thin pipelines of major companies will cause revenues to fall.

The Indian government has implemented various initiatives to increase insurance coverage and reduce healthcare costs, such as the National Rural Health Mission and Jan Aushadhi. A revised pricing policy was also proposed in 2011, which will increase government control to over 60% of drugs.

Rising income levels, changing disease patterns, increasing reach of healthcare, reduced out-of-pocket expenditure and growth of new products such as generics and biosimilars are expected to drive growth in the future.

Scope

  • Macroeconomic environment of the pharmaceutical industry in India, covering demographic analysis, drivers, and barriers
  • Important industry characteristics, looking at healthcare policies, regulations, distribution, pricing, taxation, spending, insurance and reimbursement
  • Market analysis of segments such as prescription medicines, biotechnology, over-the-counter medicines and Contract Research and Manufacturing Services (CRAMS)
  • Annualized market data from 2005 to 2010 for important therapeutic segments
  • Competitive profiling of five major domestic and international companies operating in the Indian pharmaceutical market
  • Analysis of licensing, partnership and M&A deals that took place between 2007 and 2011

Reasons to buy

  • Develop market-entry and market-expansion strategies by identifying the leading segments poised for strong growth
  • Device a more tailored country strategy through understanding key drivers of and barriers to the pharmaceutical market
  • Develop key strategic initiatives by understanding leading companies' key focus areas
  • Accelerate and strengthen your market position by identifying key companies for M&A and strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Indian Pharmaceutical Market Outlook - Introduction

3. Indian Pharmaceutical Market Outlook - Overview

  • 3.1. Global Pharmaceutical Industry Landscape
  • 3.2. Macro View of the Indian Pharmaceutical Sector
  • 3.3. Demographic Analysis
    • 3.3.1. Population Size, Growth, and Structure
    • 3.3.2. Crude Death Rate
    • 3.3.3. Infant Mortality Rate
    • 3.3.4. Life Expectancy at Birth
  • 3.4. Driver and Barriers
    • 3.4.1. Drivers
    • 3.4.2. Barriers
  • 3.5. SWOT Analysis of Indian Pharmaceutical Industry

4. Indian Pharmaceutical Market Outlook - Industry Characteristics

  • 4.1. Healthcare Policy
    • 4.1.1. National Health Policy 2002
    • 4.1.2. National Rural Health Mission
    • 4.1.3. National Urban Health Mission
  • 4.2. Intellectual Property Rights in India
    • 4.2.1. Effect of Patent Laws on Pharmaceutical Production in India
    • 4.2.2. Key Impact of the New Patent Laws on India
    • 4.2.3. Patent Act 2005 - First Step towards Improving IP Protection
    • 4.2.4. IPR Enforcement Rules 2007
    • 4.2.5. Trademarks Bill 2007
    • 4.2.6. Drugs and Cosmetics Act (Amendment) 2008
  • 4.3. Drug Distribution Structure
  • 4.4. National Pharmaceuticals Pricing Policy
    • 4.4.1. Objectives of the Present Policy
    • 4.4.2. Key Principles of National Pharmaceuticals Pricing Policy, 2011
    • 4.4.3. Principles for Drug Price Control and Determination in National Pharmaceutical Pricing Policy 2011
    • 4.4.4. Other Aspects of the Policy
    • 4.4.5. Impact Analysis of the Policy
  • 4.5. Goods and Services Tax
    • 4.5.1. An Introduction to Goods and Services Tax
    • 4.5.2. Dual Goods and Services Tax in India
    • 4.5.3. Impact on the Pharmaceutical Industry
  • 4.6. Direct Tax Code
    • 4.6.1. Tax Structure
    • 4.6.2. Incentives Available to the Pharmaceutical Sector
    • 4.6.3. Road Ahead
  • 4.7. Healthcare Spending in India
  • 4.8. Insurance and Reimbursement
    • 4.8.1. Private Health Insurance
    • 4.8.2. Health Insurance Companies Landscape

5. Indian Pharmaceutical Market Outlook - Market Analysis

  • 5.1. Market overview
    • 5.1.1. Contract Research and Manufacturing Services
    • 5.1.2. Biotech
    • 5.1.3. Over-the-Counter Drugs
    • 5.1.4. Prescription Drugs
    • 5.1.5. Herbal Medicines
  • 5.2. Market Segmentation

6. Indian Pharmaceutical Market Outlook - Market Analysis by Therapeutic Categories

  • 6.1. Market Share of Leading Therapeutic Segment
  • 6.2. Anti-Infectives
    • 6.2.1. Market Size
    • 6.2.2. Key Brands and Players
    • 6.2.3. Recent Developments
    • 6.2.4. Outlook
  • 6.3. Cardiovascular System
    • 6.3.1. Market Size
    • 6.3.2. Recent Developments
    • 6.3.3. Outlook
  • 6.4. Gastrointestinal
    • 6.4.1. Market Size
    • 6.4.2. Recent Developments
    • 6.4.3. Outlook
  • 6.5. Diabetes
    • 6.5.1. Market Size
    • 6.5.2. Recent Developments
    • 6.5.3. Outlook
  • 6.6. Central Nervous System
    • 6.6.1. Market Size
    • 6.6.2. Recent Developments
    • 6.6.3. Outlook
  • 6.7. Respiratory
    • 6.7.1. Market Size
    • 6.7.2. Recent Developments
    • 6.7.3. Outlook
  • 6.8. Dermatology
    • 6.8.1. Market Size
    • 6.8.2. Recent Developments
    • 6.8.3. Outlook
  • 6.9. Oncology
    • 6.9.1. Market Size
    • 6.9.2. Recent Developments
    • 6.9.3. Outlook

7. Indian Pharmaceutical Market Outlook - Key Trends

  • 7.1. Rapid Consolidation and Rise of Multinational Corporations in the Indian Pharmaceutical Industry
    • 7.1.1. M&A Deals
    • 7.1.2. Licensing Deals
    • 7.1.3. Partnership Deals
  • 7.2. Patent Litigations Favoring Generics
    • 7.2.1. Indian Patent Office Revokes Patent for Pfizer's Cancer Drug Sutent (sunitinib)
    • 7.2.2. Indian Appeals Body Dismisses Bayer's Plea for Stay on Natco's Generic Nexavar (sorafenib)
    • 7.2.3. Delhi High Court Rules in Favor of Cipla in Roche's Tarceva (erlotinib) Patent Lawsuit
    • 7.2.4. Indian Supreme Court Asks Novartis to Scale Down Price of Cancer Drug Glivec (imatinib)
  • 7.3. Increasing Importance of Rural Marketing in India
    • 7.3.1. Case Study - Novartis Arogya Parivar Case Study
  • 7.4. Product Localization and India-Specific Pricing
    • 7.4.1. Case Study - GlaxoSmithKline, Localized Business Model
  • 7.5. Sales Strategies
    • 7.5.1. Case Study - Mankind, Sales Excellence
  • 7.6. Patented Products Introduced in Niche Segments
    • 7.6.1. Case Study - Merck's Successful Strategy for Patented Products
  • 7.7. Actions Taken by Indian Government against Counterfeit Drugs

8. Indian Pharmaceutical Market Outlook - Competitive Landscape

  • 8.1. Key Foreign Companies
    • 8.1.1. Sanofi
    • 8.1.2. Roche
    • 8.1.3. AstraZeneca
    • 8.1.4. GlaxoSmithKline
    • 8.1.5. Abbott Laboratories
  • 8.2. Key Domestic Companies
    • 8.2.1. Dr. Reddy's Laboratories
    • 8.2.2. Lupin
    • 8.2.3. Cipla Limited
    • 8.2.4. Ranbaxy Laboratories Limited
    • 8.2.5. Biocon

9. Indian Pharmaceutical Market Outlook - The Way Forward

  • 9.1. Outlook for the Indian Pharmaceutical Industry
  • 9.2. Risks
    • 9.2.1. Currency Fluctuation and Financial Problems will make it Difficult to Sustain Growth
    • 9.2.2. Regulatory Hurdles
    • 9.2.3. Financial Disparity
    • 9.2.4. Intellectual Property Concerns
  • 9.3. Recommendations
    • 9.3.1. Improved Links between Industry and Academia
    • 9.3.2. Focus on R&D Initiatives and Skilled Manpower
    • 9.3.3. Support for Clinical Trials Sector
    • 9.3.4. Quality Drugs to be made Affordable and Accessible
  • 9.4. Opportunities Ahead
  • 9.5. Strategies for Future Success
    • 9.5.1. Increasing Importance of Biosimilars
    • 9.5.2. Rural Markets

10. Indian Pharmaceutical Market Outlook - Appendix

  • 10.1. Market Definitions
  • 10.2. Abbreviations
  • 10.3. Bibliography
  • 10.4. Research Methodology
    • 10.4.1. Coverage
    • 10.4.2. Secondary Research
    • 10.4.3. Primary Research
    • 10.4.4. Expert Panel Validation
  • 10.5. Contact Us
  • 10.6. Disclaimer

List of Tables

  • Table 1: Pharmaceutical Market, India, Share of Pharmaceutical Products in Total Exports and Imports (%), 2012
  • Table 2: Pharmaceutical Market, India, Population by Age Group (%), 2001-2026
  • Table 3: Pharmaceutical Market, India, Crude Death Rate (per 1,000 Population), 1981-2009
  • Table 4: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 1980-1998
  • Table 5: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 1999-2009
  • Table 6: Pharmaceutical Market, India, Ceiling Price Reduction and Impact, 2012
  • Table 7: Pharmaceutical Market, India, Healthcare Expenditure among BRIC Countries, 2012
  • Table 8: Pharmaceutical Market, India, Indian Biosimilar Companies with Marketed Products in India, 2010
  • Table 9: Pharmaceutical Market, India, Retail Market Revenue ($bn), 2007-2011
  • Table 10: Pharmaceutical Market, India, Hospital Market Revenue ($m), 2007-2011
  • Table 11: Pharmaceutical Market, India, Anti-Infectives Market Revenue, ($bn), 2005-2010
  • Table 12: Pharmaceutical Market, India, Anti-Infectives, Major Companies and Brands, 2011
  • Table 13: Pharmaceutical Market, India, Cardiovascular Market Revenue ($m), 2005-2010
  • Table 14: Pharmaceutical Market, India, Gastrointestinal Market Revenue, ($m), 2005-2010
  • Table 15: Pharmaceutical Market, India, Diabetes Market Revenue ($m), 2005-2010
  • Table 16: Pharmaceutical Market, India, Central Nervous System Market Revenue ($m), 2005-2010
  • Table 17: Pharmaceutical Market, India, Respiratory Market Revenue ($m), 2005-2010
  • Table 18: Pharmaceutical Market, India, Dermatology Market Revenue ($m), 2005-2010
  • Table 19: Pharmaceutical Market, India, Oncology Market Revenue ($m), 2005-2010
  • Table 20: Pharmaceutical Market, India, Dr. Reddy's Laboratories, Strategic Consolidations, 2011-2012
  • Table 21: Pharmaceutical Market, India, Lupin, Strategic Consolidations, 2011
  • Table 22: Pharmaceutical Market, India, Cipla, Strategic Consolidations, 2012
  • Table 23: Pharmaceutical Market, India, Ranbaxy, Strategic Consolidations, 2011-2012
  • Table 24: Pharmaceutical Market, India, Biocon, Strategic Consolidations, 2011-2012

List of Figures

  • Figure 1: Pharmaceutical Market, India, ANDA Filings by Indian Companies, 2012
  • Figure 2: Pharmaceutical Market, India, Growth in Pharmaceutical Products Trade, (%), 2006-2011
  • Figure 3: Pharmaceutical Market, India, Population by Age Group (%), 2001-2026
  • Figure 4: Pharmaceutical Market, India, Crude Death Rate (per 1,000 Population), 1981-2009
  • Figure 5: Pharmaceutical Market, India, Infant Mortality Rate by Sex (per 1,000 Live Births), 1980-2009
  • Figure 6: Pharmaceutical Market, India, Life Expectancy at Birth, 1901-2025
  • Figure 7: Pharmaceutical Market, India, Healthcare Indicators in BRIC Countries, 2012
  • Figure 8: Pharmaceutical Market, India, Drivers and Barriers, 2012
  • Figure 9: Pharmaceutical Market, India, Doctors and Nurses (per 10,000 population), 2010
  • Figure 10: Pharmaceutical Market, India, SWOT Analysis
  • Figure 11: Pharmaceutical Market, India, NRHM Progress, 2011
  • Figure 12: Pharmaceutical Market, India, Intellectual Property Rights Protection Framework, 2010
  • Figure 13: Pharmaceutical Market, India, Regulatory Landscape, Intellectual Property Rights Protection, 1963-2005
  • Figure 14: Pharmaceutical Market, India, Drug Distribution System, 2012
  • Figure 15: Pharmaceutical Market, India, Healthcare Expenditure, 2009
  • Figure 16: Pharmaceutical Market, India, Healthcare Expenditure among BRIC Countries, 2012
  • Figure 17: Pharmaceutical Market, India, Health Insurance Companies Landscape, 2012
  • Figure 18: Pharmaceutical Market, India, Services Outsourced in Value Chain (%), 2011
  • Figure 19: Pharmaceutical Market, India, Biotechnology Market Revenue ($m), 2003-2011
  • Figure 20: Pharmaceutical Market, India, Biotechnology Market Segmentation (%), 2011
  • Figure 21: Pharmaceutical Market, India, Market by Sub-sector (%), 2011
  • Figure 22: Pharmaceutical Market, India, Retail Market Revenue ($bn), 2007-2011
  • Figure 23: Pharmaceutical Market, India, Hospital Market Revenue ($m), 2007-2011
  • Figure 24: Pharmaceutical Market, India, Market Share by Therapy Area, 2005 and 2010
  • Figure 25: Pharmaceutical Market, India, Anti-Infectives Market Revenue ($bn), 2005-2010
  • Figure 26: Pharmaceutical Market, India, Cardiovascular Market Revenue ($m), 2005-2010
  • Figure 27: Pharmaceutical Market, India, Gastrointestinal Market Revenue ($m), 2005-2010
  • Figure 28: Pharmaceutical Market, India, Diabetes Market Revenue ($m), 2005-2010
  • Figure 29: Pharmaceutical Market, India, Central Nervous System Market Revenue ($m), 2005-2010
  • Figure 30: Pharmaceutical Market, India, Respiratory Market Revenue ($m), 2005-2010
  • Figure 31: Pharmaceutical Market, India, Dermatology Market Revenue ($m), 2005-2010
  • Figure 32: Pharmaceutical Market, India, Oncology Market Revenue ($m), 2005-2010
  • Figure 33: Pharmaceutical Market, India, Number of M&A Deals, 2007-2012
  • Figure 34: Pharmaceutical Market, India, M&A Deals, Deals by Value (%), 2007-2012
  • Figure 35: Pharmaceutical Market, India, Number of Licensing Deals, 2007-2012
  • Figure 36: Pharmaceutical Market, India, Licensing Deals, Deals by Value (%), 2007-2012
  • Figure 37: Pharmaceutical Market, India, Number of Partnership Deals, 2007-2012
  • Figure 38: Pharmaceutical Market, India, Partnership Deals, Deals by Value (%), 2007-2012
  • Figure 39: Pharmaceutical Market, India, Novartis Arogya Parivar Marketing Mix, 2012
  • Figure 40: Pharmaceutical Market, India, Novartis Arogya Parivar, Factsheet, 2012
  • Figure 41: Pharmaceutical Market, India, Mankind Sales Strategies, 2012
Back to Top